Goldring SR (2002) Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 14:406–410CrossRefPubMedGoogle Scholar

Redlich K, Hayer S, Ricci R et al (2002) Osteoclasts are essential for TNF- alpha-mediated joint destruction. J Clin Invest 110:1419–1427CrossRefPubMedPubMedCentralGoogle Scholar

Schett G (2007) Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Res Ther 9:203–208CrossRefPubMedPubMedCentralGoogle Scholar

Goldring SR (2003) Inflammatory mediators as essential elements in bone remodeling. Calcif Tissue Int 73:97–100CrossRefPubMedGoogle Scholar

Polzer K, Zwerina J, Schett G et al (2008) Inflammation and destruction of the joints – the Wnt pathway. Joint Bone Spine 75:105–107CrossRefPubMedGoogle Scholar

Walsh NC, Crotti TN, Goldring SR et al (2005) Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 208:228–251CrossRefPubMedGoogle Scholar

Lam J, Takeshita S, Barker JE et al (2000) TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106:1481–1488CrossRefPubMedPubMedCentralGoogle Scholar

Kotake S, Udagawa N, Takahashi N et al (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103:1345–1352CrossRefPubMedPubMedCentralGoogle Scholar

Lee SK, Gardner AE, Kalinowski JF et al (2006) RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production. Bone 38:678–685CrossRefPubMedGoogle Scholar

Kostenuik PJ (2005) Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5:618–625CrossRefPubMedGoogle Scholar

Gravallese EM, Galson DL, Goldring SR et al (2001) The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. Arthritis Res 3:6–12CrossRefPubMedGoogle Scholar

Pap T, Muller-Ladner U, Gay RE et al (2000) Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res 2:361–367CrossRefPubMedPubMedCentralGoogle Scholar

Neumann E, Lefèvre S, Zimmermann B et al (2010) Rheumatoid arthritis progression mediated by activated synovial fibroblasts. Trends Mol Med 16(458):468Google Scholar

Bartok B, Firestein GS (2010) Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 233:233–255CrossRefPubMedPubMedCentralGoogle Scholar

Huber LC, Distler O, Tarner I et al (2006) Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford) 45:669–675CrossRefGoogle Scholar

Muller-Ladner U, Gay S (2002) MMPs and rheumatoid synovial fibroblasts: Siamese twins in joint destruction? Ann Rheum Dis 61:957–959CrossRefPubMedPubMedCentralGoogle Scholar

Takayanagi H, Iizuka H, Juji T et al (2000) Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43:259–269CrossRefPubMedGoogle Scholar

Dankbar B, Fennen M, Brunert D et al (2015) Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice. Nat Med 21:1085–1090CrossRefPubMedGoogle Scholar

Wehmeyer C, Frank S, Beckmann D et al (2016) Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction. Sci Transl Med 8:330ra34CrossRefGoogle Scholar

McPherron AC, Lawler AM, Lee SJ (1997) Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387:83–90CrossRefPubMedGoogle Scholar

Bradley L, Yaworsky PJ, Walsh FS (2008) Myostatin as a therapeutic target for musculoskeletal disease. Cell Mol Life Sci 65:2119–2124CrossRefPubMedGoogle Scholar

Hamrick MW (2003) Increased bone mineral density in the femora of GDF8 knockout mice. Anat Rec 272:388–391CrossRefGoogle Scholar

Hamrick MW, Pennington C, Byron CD (2003) Bone architecture and disc degeneration in the lumbar spine of mice lacking GDF-8 (myostatin). J Orthop Res 21:1025–1032CrossRefPubMedGoogle Scholar

Bialek P, Parkington J, Warner L et al (2008) Mice treated with a myostatin/GDF-8 decoy receptor, ActRIIB-Fc, exhibit a tremendous increase in bone mass. Bone 42:S46CrossRefGoogle Scholar

Kellum E, Starr H, Arounleut P et al (2009) Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume. Bone 44:17–23CrossRefPubMedGoogle Scholar

Keffer J, Probert L, Cazlaris H et al (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10:4025–4031PubMedPubMedCentralGoogle Scholar

Okamoto M, Murai J, Yoshikawa H et al (2006) Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development. J Bone Miner Res 21:1022–1033CrossRefPubMedGoogle Scholar

Krishnan V, Bryant HU, Macdougald OA (2006) Regulation of bone mass by Wnt signaling. J Clin Invest 116:1202–1209CrossRefPubMedPubMedCentralGoogle Scholar

Glass DA, Karsenty G (2006) Molecular bases of the regulation of bone remodeling by the canonical Wnt signaling pathway. Curr Top Dev Biol 73:43–84CrossRefPubMedGoogle Scholar

Wodarz A, Nusse R (1998) Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 14:59–88CrossRefPubMedGoogle Scholar

Bodine PV, Komm BS (2006) Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord 7:33–39CrossRefPubMedGoogle Scholar

Johnson ML, Harnish K, Nusse R et al (2004) LRP5 and Wnt signaling: a union made for bone. J Bone Miner Res 19:1749–1757CrossRefPubMedGoogle Scholar

Li J, Sarosi I, Cattley RC et al (2006) Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39:754–766CrossRefPubMedGoogle Scholar

Mao B, Wu W, Li Y et al (2001) LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 411:321–325CrossRefPubMedGoogle Scholar

Li X, Zhang Y, Kang H et al (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883–19887CrossRefPubMedGoogle Scholar

Semenov M, Tamai K, He X (2005) SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 280:26770–26775CrossRefPubMedGoogle Scholar

Poole KE, van Bezooijen RL, Loveridge N et al (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842–1844PubMedGoogle Scholar

Diarra D, Stolina M, Polzer K et al (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156–163CrossRefPubMedGoogle Scholar

Recker RR, Benson CT, Matsumoto T et al (2015) A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res 30:216–224CrossRefPubMedGoogle Scholar

McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412–420CrossRefPubMedGoogle Scholar

Bertolini DR, Nedwin GE, Bringman TS et al (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319:516–518Google Scholar

Lange U, Teichmann J, Muller-Ladner U et al (2005) Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology (Oxford) 44:1546–1548Google Scholar